Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Interest Expenses (2023)

Pasithea Therapeutics (KTTA) has disclosed Interest Expenses for 1 consecutive years, with -$117191.0 as the latest value for Q2 2023.

  • Quarterly Interest Expenses changed N/A to -$117191.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was -$117191.0 through Mar 2024, down 1934.55% year-over-year, with the annual reading at $102.0 for FY2022, 79.92% down from the prior year.
  • Interest Expenses hit -$117191.0 in Q2 2023 for Pasithea Therapeutics, down from $6388.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $6388.0 in Q1 2023 to a low of -$117191.0 in Q2 2023.